Month: August 2025

Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients KANSAS CITY, Kan., Aug. 06, 2025 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for CTx-1301(dexmethylphenidate HCl), the company’s lead asset for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). CTx-1301 is a novel, extended-release tablet formulation of dexmethylphenidate designed to deliver fast onset, entire active-day efficacy, and a smooth pharmacokinetic...

Yokneam Illit, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) — Wearable Devices Ltd. (the “Company” or “Wearable Devices”) (Nasdaq: WLDS, WLDSW), a technology growth company specializing in artificial intelligence (“AI”)-powered touchless sensing wearables, today announced the launch of an innovative project to advance human-machine interfaces (“HMI”) for military applications. This cutting-edge initiative introduces a touchless neural control system that would enable soldiers to operate critical tactical systems seamlessly, enhancing operational efficiency and safety in high-stakes environments. Leveraging its proprietary neural interface technology, Wearable Devices is developing an innovative solution that would allow soldiers to interact with communication and control systems using intuitive gestures, without compromising their...

Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontline TherapyCHICAGO and FORT WORTH, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the initiation of the Phase 1b trial of elraglusib in combination with Incyte’s PD-1 inhibitor, retifanlimab, and modified FOLFIRINOX (mFOLFIRINOX) as frontline therapy in advanced pancreatic adenocarcinoma. The trial is being conducted in collaboration with UPMC Hillman Cancer Center and Incyte Corporation. The Investigator-Initiated Phase 1b open-label, single-arm RiLEY...

Presented data highlights the potential of Annamycin for treating broad range of human cancers, including high-need oncology indications  Annamycin currently in late-stage clinical development in combination with cytarabine for the treatment of AML; Anticipated preliminary data readout in 2H 2025 HOUSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the presentation of encouraging preclinical data for its lead drug candidate, Annamycin, also known by its non-proprietary name of naxtarubicin, which demonstrated significant efficacy against various primary and metastatic liver cancers, including hepatocellular carcinoma (HCC), colorectal...

Bowie, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) — Blink Charging Co. (NASDAQ: BLNK) (“Blink” or the “Company”), a leading global, owner, operator, and provider of electric vehicle (EV) charging equipment and services, today announced that it has rescheduled its previously announced earnings conference call. The Company will now host a conference call to review second quarter 2025 results after the stock market closes on Monday, August 18. Blink will issue a press release reporting its results, which will be available on the Investor Relations section of its website. Management will then host a conference call and webcast for investors and analysts at 4:30 P.M. ET to discuss the results. To access the live webcast, log onto the Blink Charging website at www.blinkcharging.com, and click on the News/Events section of the Investor Relations...

Trial now over 60% enrolled with 125 of 200 anticipated patients Recent new site activation brings total clinical trial sites to 16 Interim analysis of first 100 patients remains on track for 3Q 2025 DENVER, Aug. 06, 2025 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it has successfully reached enrollment of 125 patients in the NEUTRALIZE-AKI pivotal clinical trial. Additionally, it has activated Methodist Hospital Metropolitan of San Antonio, Texas, as its 16th clinical trial site. The company also reported that it remains on track to receive results from the per protocol prespecified interim analysis of the first 100 patients in the trial...

BERKELEY, Calif, Aug. 06, 2025 (GLOBE NEWSWIRE) — Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, provides a strategy overview and business update from Chairman and CEO, Ben Hwang, Ph.D. in the following Letter to Shareholders: To our valued shareholders, In the last two months, Profusa has achieved significant milestones, including securing investment and becoming a public company that is trading on the Nasdaq Market under the ticker PFSA on July 14, 2025. With these essential steps behind us, we are now fully committed to bring our groundbreaking personalized biochemistry technology platform to the clinical community and drive growth in our business. We...